The FDA is hoping that rapidly-advancing artificial intelligence capabilities will not pass it by.
The agency’s Center for Drug Evaluation and Research (CDER) has launched …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Investigation shows how bacterial adhesins contribute to colon cancer mutations, suggesting new avenues for therapeutic intervention in colorectal cancer.
MADRID — Treatment with cemiplimab (Libtayo) followed by surgery showed encouraging survival rates in patients with resectable stage II-IV cutaneous squamous cell carcinoma (SCC), according
Vanflyta is claimed to be the first and only FLT3 inhibitor to receive FDA approval for treating FLT3-ITD positive AML. Credit: Nemes Laszlo / Shutterstock.com.